CR6491A - HIV IMMUNOGENIC COMPOSITIONS AND METHODS - Google Patents
HIV IMMUNOGENIC COMPOSITIONS AND METHODSInfo
- Publication number
- CR6491A CR6491A CR6491A CR6491A CR6491A CR 6491 A CR6491 A CR 6491A CR 6491 A CR6491 A CR 6491A CR 6491 A CR6491 A CR 6491A CR 6491 A CR6491 A CR 6491A
- Authority
- CR
- Costa Rica
- Prior art keywords
- hiv
- immunogenic compositions
- antigen
- mammal
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención ofrece composiciones inmugénicas que incrementan los niveles de B- quimiocina en un mamífero.Las composiciones inmugénicas contienen un antígeno de VIH, una mólecula de ácido nucleico aislada que contiene una secuencia inmunoestimuladora (ISS) y un adyuvnate. El antígeno de VIH puede ser un virus de VIH entero muerto sin la proteina de envoltura externa gp120. Alternativamente, el antígeno de VIH puede ser un virus de VIH entero muerto, o bien un antígeno p24. Se proporciona también un método para inhibir el SIDA, mediante el incremento de la producción de B-quimiciona en el mamífero mediante la administración al mamífero de una composición inmunogénica que contiene un antígeno de VIH, una molécula de ácido nucleico aislada que contiene una secuencia inmunoestimuladora (ISS) y un adyuvante.The invention offers immunogenic compositions that increase levels of B-chemokine in a mammal. Immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule that contains an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a dead whole HIV virus without the outer envelope protein gp120. Alternatively, the HIV antigen can be a dead whole HIV virus, or a p24 antigen. A method for inhibiting AIDS is also provided by increasing the production of B-chemocyte in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence. (ISS) and an adjuvant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13276299P | 1999-05-06 | 1999-05-06 | |
US15066799P | 1999-08-25 | 1999-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR6491A true CR6491A (en) | 2005-05-31 |
Family
ID=26830710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR6491A CR6491A (en) | 1999-05-06 | 2001-10-25 | HIV IMMUNOGENIC COMPOSITIONS AND METHODS |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1176978A2 (en) |
AP (1) | AP1891A (en) |
AU (1) | AU4992900A (en) |
BR (1) | BR0010323A (en) |
CA (1) | CA2372960C (en) |
CR (1) | CR6491A (en) |
OA (1) | OA11937A (en) |
WO (1) | WO2000067787A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP1077722B1 (en) | 1998-05-22 | 2006-08-09 | Ottawa Health Research Institute | Methods and products for inducing mucosal immunity |
CA2358385C (en) | 1998-12-31 | 2013-08-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
DE60023300T2 (en) * | 1999-06-29 | 2006-07-06 | Glaxosmithkline Biologicals S.A. | USE OF CPG AS ADJUVANS FOR HIV PULP |
ES2347525T3 (en) | 2000-12-27 | 2010-11-02 | Dynavax Technologies Corporation | IMMUNOMODULATING POLINUCLEOTIDES AND METHODS FOR USERS. |
SG152045A1 (en) * | 2001-01-26 | 2009-05-29 | Immune Response Corp Inc | Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment |
EP2423335B1 (en) | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
EP1411770A4 (en) | 2001-07-05 | 2006-05-10 | Chiron Corp | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
EP1446162B1 (en) | 2001-08-17 | 2008-10-15 | Coley Pharmaceutical GmbH | Combination motif immune stimulatory oligonucleotides with improved activity |
AR045702A1 (en) | 2001-10-03 | 2005-11-09 | Chiron Corp | COMPOSITIONS OF ASSISTANTS. |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
JP2005532067A (en) * | 2002-07-03 | 2005-10-27 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Nucleic acid composition for stimulating immune response |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
JP2006515277A (en) | 2002-10-29 | 2006-05-25 | コーリー ファーマシューティカル グループ, リミテッド | Methods and products for treatment and prevention of hepatitis C virus infection |
JP2006512927A (en) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5 'CPG nucleic acids and methods of use thereof |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
KR101309501B1 (en) | 2002-12-23 | 2013-09-24 | 다이나박스 테크놀로지 코퍼레이션 | Immunostimulatory sequence oligonucleotides and methods of using the same |
WO2005021726A2 (en) * | 2003-08-28 | 2005-03-10 | The Immune Response Corporation | Immunogenic hiv compositions and related methods |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
PT2078080E (en) | 2006-09-27 | 2015-09-18 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity |
WO2010051820A1 (en) * | 2008-11-10 | 2010-05-14 | Aarhus Universitet | Multiplexed cytokine vaccination |
US9636410B2 (en) | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1005368B1 (en) * | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
ATE252596T1 (en) * | 1997-06-06 | 2003-11-15 | Dynavax Tech Corp | IMMUNO-STIMULATING OLIGONUCLEOTIDES, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF |
-
2000
- 2000-05-05 OA OA1200100291A patent/OA11937A/en unknown
- 2000-05-05 WO PCT/US2000/012495 patent/WO2000067787A2/en active Application Filing
- 2000-05-05 AU AU49929/00A patent/AU4992900A/en not_active Abandoned
- 2000-05-05 EP EP00932163A patent/EP1176978A2/en not_active Withdrawn
- 2000-05-05 AP APAP/P/2001/002300A patent/AP1891A/en active
- 2000-05-05 BR BR0010323-3A patent/BR0010323A/en not_active IP Right Cessation
- 2000-05-05 CA CA002372960A patent/CA2372960C/en not_active Expired - Fee Related
-
2001
- 2001-10-25 CR CR6491A patent/CR6491A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU4992900A (en) | 2000-11-21 |
AP2001002300A0 (en) | 2001-12-31 |
WO2000067787A3 (en) | 2001-04-26 |
AP1891A (en) | 2008-09-23 |
BR0010323A (en) | 2002-01-08 |
OA11937A (en) | 2006-04-12 |
WO2000067787A2 (en) | 2000-11-16 |
CA2372960C (en) | 2006-03-28 |
CA2372960A1 (en) | 2000-11-16 |
EP1176978A2 (en) | 2002-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR6491A (en) | HIV IMMUNOGENIC COMPOSITIONS AND METHODS | |
ATE331530T1 (en) | PROTEASOME INFLUENZA VIRUS VACCINE COMPOSITION G | |
CO5680456A2 (en) | COMPOSITIONS OF VACCINES THAT INCLUDE LIPOOLIGOSACARIDS OF IMMUNOTIPE L2 AND / OR L3 FROM LGTB-NEISSERIA MINIGITIDIS | |
ES2129386T1 (en) | INFLUENZA VACCINE. | |
PE20071098A1 (en) | IMMUGENIC COMPOSITION CONTAINING AS ADJUVANTS A SAPONIN AND A POLYSACCHARIDE | |
DK0778888T3 (en) | Antigen-labeled non-infectious retrovirus-like particle | |
BR0107679A (en) | Outer membrane vesicle (omv) vaccine comprising neisseria meningitidis serum group b outer membrane proteins | |
ES2421543T3 (en) | Method for the preparation of PRRS viruses and proteins, and diagnostic test kits for detection | |
MY136081A (en) | Modified hiv - 1gag p17 peptide and immunogenic composition | |
AR050102A1 (en) | HIV FUSION POLIPEPTIDES FOR AIDS PREVENTION AND / OR TREATMENT | |
ATA155598A (en) | NEW INFLUENCE VIRUS VACCINE COMPOSITION | |
EA200201271A1 (en) | INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1 | |
MX9306841A (en) | UREASE BASED VACCINE AGAINST HELICOBACTER INFECTION IN MAMMALS. | |
DK1104306T3 (en) | Preparations of CpG and Saponin Adjuvants and Methods for Using Them | |
DE68927348D1 (en) | ARTIFICIAL VACCINE AGAINST AIDS VIRUS | |
ES2140076T3 (en) | VACCINES CONTAINING A SAPONIN AND A STEROL. | |
MY129263A (en) | Vaccine composition | |
CR8251A (en) | IMMUNOGENIC HIV COMPOSITIONS AND RELATED METHODS | |
ECSP045300A (en) | VIRAL ANTIGENS | |
HUP0002322A2 (en) | Multivalent vaccine composition with mixed carrier | |
DK1326636T3 (en) | vaccine Composition | |
ES8603756A1 (en) | Immunogenic composition comprising live encysted protozoa. | |
HK1044778A1 (en) | Hiv-peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv hiv | |
WO2005013918A3 (en) | Compositions, methods and kits relating to poxvirus subunit vaccines | |
EA200400690A1 (en) | NUCLEOSIDES, THEIR PREPARATIONS AND THEIR APPLICATION AS VIRAL RNA POLYMERASE INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |